Prescription drug · ANDA
Hydroxyzine Pamoate NDC 60687-707
Hydroxyzine pamoate 50 mg/1 · Capsule · Oral · American Health Packaging
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60687-707-01 | 60687070701 | 100 BLISTER PACK in 1 CARTON (60687-707-01) / 1 CAPSULE in 1 BLISTER PACK (60687-707-11)Marketed from May 24, 2023 | |
| 60687-707-65 | 60687070765 | 50 BLISTER PACK in 1 CARTON (60687-707-65) / 1 CAPSULE in 1 BLISTER PACK (60687-707-11)Marketed from Dec 21, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Hydroxyzine Pamoate
- Generic name (nonproprietary)
- hydroxyzine pamoate
- Active ingredients
- Hydroxyzine pamoate — 50 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- American Health Packaging
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 088487
- Marketing start
- Listing expires
- Other FDA classes
- Histamine Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 60687-707_276f89cd-550c-fced-e063-6394a90a4181SPL ID 276f89cd-550c-fced-e063-6394a90a4181SPL set ID e1a7d95c-e6f6-4a89-90b0-002156e90b41RxCUI 995253, 995278UNII M20215MUFR
- Pharmacologic class
- Antihistamine
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460687070701followed by a unit qualifier and the quantityPackage 60687-0707-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 088487
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Hydroxyzine Pamoate | Hydroxyzine pamoate 50 mg/1 | CapsuleOral | Asclemed USA, Inc. | 76420-921 |
| Hydroxyzine Pamoate | Hydroxyzine pamoate 50 mg/1 | CapsuleOral | Teva Pharmaceuticals USA, Inc. | 0555-0302 |
| Hydroxyzine Pamoate | Hydroxyzine pamoate 50 mg/1 | CapsuleOral | Northwind Health Company, LLC | 51655-252 |